The Post-Exclusivity Event Horizon: Strategic Forecasting of Generic and Biosimilar Entry
Pharmaceutical life cycle management begins earlier and ends later to maximize stakeholder value in all phases of drug development.
Insights
DrugPatentWatch in the news: The Biologic Patent Transparency Act.
For readers following the the Biologic Patent Transparency Act, DrugPatentWatch has recently been cited in an article describing the act as
DrugPatentWatch in the news: The Biologic Patent Transparency Act. Read Post »
The Device Patent Wall: How Pharma Buys 4.7 Extra Years of Drug Exclusivity — and What It Costs Everyone
1. What This Article Covers and Why It Matters Now The baseline 20-year patent term for a small molecule drug
Drug Prices Are Breaking Healthcare Systems: The Complete Analyst’s Guide to Patent Strategy, Cost Containment, and the IRA’s Real Impact
Healthcare systems including hospitals are taking care-related and business-related steps to cope with rapidly increasing drug prices.
Expired Drug Patents Are Worth More Than You Think: The Complete Playbook for IP Teams, Portfolio Managers, and Generic Entrants
Information contained in expired drug patents can be invaluable to researchers developing new products, but caution is required to avoid legal problems.
Flat Fee, Unlimited Drugs: The Payer License Agreement Playbook Reshaping Pharmaceutical Access
A comprehensive analysis for pharma IP teams, portfolio managers, payer strategy leads, and institutional investors examining the structural economics, IP
Day 181 Generic Drug Launch: The Definitive Analyst’s Guide to Identifying, Timing, and Winning Generic Entry Opportunities
The global generic drugs market was valued at $468.08 billion in 2025 and is projected to reach $728.64 billion by
Cancer Drug ROI: Why Pharma Makes $14.50 for Every $1 Spent on R&D
An evidence-based analysis of FDA-approved oncology drug economics, patent strategy, and what the numbers actually mean for payers, investors, and
Cancer Drug ROI: Why Pharma Makes $14.50 for Every $1 Spent on R&D Read Post »
What the Most Successful Drug Launches Reveal About Modern Pharma IP, Pricing, and Market Strategy
Recent successful drug launches indicate a trend toward more specialized, high-priced drugs that treat less-common medical conditions.
